
















We Claim


1. A compound selected from the group consisting of:



,

,

,

,

,

,

,

,



,

,

,

, ~~and~~

,

,

,



,



,



,



,



,



,



,



,



,


,


,



,


, and


,


or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

14. The compound of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

15. The compound of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

16. The compound of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

17. The compound of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

18. The compound of claim 1, having the following structure:




or a pharmaceutically acceptable salt thereof.

19. The compound of claim 1, having the following structure:




.

20. The compound of claim 1, having the following structure:




.


21. The compound of claim 1, having the following structure:




22. The compound of claim 1, having the following structure:




23. The compound of claim 1, having the following structure:




24. The compound of claim 1, having the following structure:




25. The compound of claim 1, having the following structure:




26. The compound of claim 1, having the following structure:




27. The compound of claim 1, having the following structure:




28. The compound of claim 1, having the following structure:




29. The compound of claim 1, having the following structure:




30. The compound of claim 1, having the following structure:




31. The compound of claim 1, having the following structure:




32. The compound of claim 1, having the following structure:




33. The compound of claim 1, having the following structure:



34. The compound of claim 1, having the following structure:



35. The compound of claim 1, having the following structure:



36. A pharmaceutical composition, comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
37. Use of a compound of claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament treating and/or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease.
38. The use of claim 37, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is selected from the group consisting of: psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, hidradenitis suppurativa, bullous pemphigold, atopic dermatitis, vitiligo, multiple sclerosis, asthma, uveitis, chronic obstructive pulmonary disorder, multiple myeloma, and systemic lupus erythematosus.
39. The use of claim 37, wherein the compound, or pharmaceutically acceptable salt thereof, is to be administered orally.
40. The use of claim 37, wherein the compound, or pharmaceutically acceptable salt thereof, is to be administered as a tablet or a capsule.
41. The use of claim 37, wherein the IL-17A-mediated inflammatory syndrome, disorder, or disease is systemic lupus erythematosus.
42. The use of claim 37, wherein the IL-17A-mediated inflammatory syndrome, disorder, or disease is psoriatic arthritis.
43. The use of claim 37, wherein the IL-17A-mediated inflammatory syndrome, disorder, or disease is psoriasis.
44. The use of claim 37, wherein the IL-17A-mediated inflammatory syndrome, disorder, or disease is atopic dermatitis.
45. The use of claim 37, wherein the compound, or a pharmaceutically acceptable salt thereof, is to be administered in combination with an additional therapeutic agent.
46. The use of claim 37, wherein the compound, or a pharmaceutically acceptable salt thereof, and the additional therapeutic agent are to be administered concurrently.
47. The use of claim 37, wherein the compound, or a pharmaceutically acceptable salt thereof, and the additional therapeutic agent are to be administered sequentially.